MarÃ-a Teresa Ãlvarez RomÃ¡n

List of Publications by Year
in descending order

48 papers	410 citations	840585 11 h-index	794469 19 g-index
50 all docs	50 docs citations	50 times ranked	606 citing authors

#	Article	IF	Citations
1	The value of HEAD-US system in detecting subclinical abnormalities in joints of patients with hemophilia. Expert Review of Hematology, 2018, 11, 253-261.	1.0	49
2	Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. International Journal of Hematology, 2017, 106, 508-516.	0.7	39
3	Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. European Journal of Haematology, 2016, 97, 297-302.	1.1	34
4	Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists. Thrombosis and Haemostasis, 2019, 119, 645-659.	1.8	31
5	Platelet and immune characteristics of immune thrombocytopaenia patients nonâ€responsive to therapy reveal severe immune dysregulation. British Journal of Haematology, 2020, 189, 943-953.	1.2	27
6	Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage. Archivos De Bronconeumologia, 2022, 58, 117-124.	0.4	20
7	Registry of patients with congenital bleeding disorders and COVIDâ€19 in Madrid. Haemophilia, 2020, 26, 773-778.	1.0	18
8	Management of acquired hemophilia A: results from the Spanish registry. Blood Advances, 2021, 5, 3821-3829.	2.5	18
9	Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors. European Journal of Haematology, 2016, 96, 461-474.	1.1	15
10	Thromboprophylaxis in a patient with COVIDâ€19 and severe hemophilia A on emicizumab prophylaxis. Journal of Thrombosis and Haemostasis, 2020, 18, 2202-2204.	1.9	15
11	HJHS 2.1 and HEAD-US assessment in the hemophilic joints: How do their findings compare?. Blood Coagulation and Fibrinolysis, 2020, 31, 387-392.	0.5	14
12	Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 1395-1406.	1.8	13
13	Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEADâ€US) score. Haemophilia, 2019, 25, 144-153.	1.0	11
14	COVIDâ€19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery. Haemophilia, 2021, 27, e137-e139.	1.0	11
15	Clinical assessment and point of care ultrasonography: How to diagnose haemophilic synovitis. Haemophilia, 2022, 28, 138-144.	1.0	11
16	Arthropathy in people with mild haemophilia: Exploring risk factors. Thrombosis Research, 2022, 211, 19-26.	0.8	9
17	Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEADâ€US system. Haemophilia, 2021, 27, 479-487.	1.0	8
18	What COVID-19 can mean for people with hemophilia beyond the infection risk. Expert Review of Hematology, 2020, 13, 1073-1079.	1.0	7

#	Article	IF	Citations
19	Applying World Health Organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia. Expert Review of Hematology, 2021, 14, 429-436.	1.0	7
20	The factor VIII treatment history of nonâ€severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEADâ€US system. Journal of Thrombosis and Haemostasis, 2021, 19, 2638-2641.	1.9	7
21	Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. Blood Reviews, 2021, 50, 100833.	2.8	6
22	Determining the value contribution of emicizumab (Hemlibra^{Â®}) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. Global & Regional Health Technology Assessment, 2019, 2019, 228424031988053.	0.2	5
23	Clinical trials and Haemophilia during the COVIDâ€19 pandemic: Madrid's experience. Haemophilia, 2020, 26, e247-e249.	1.0	5
24	Total knee arthroplasty in hemophilia: lessons learned and projections of whatâ€™s next for hemophilic knee joint health. Expert Review of Hematology, 2022, 15, 65-82.	1.0	5
25	Intraâ€articular injections in people with haemophilia in the COVIDâ€19 era. Haemophilia, 2020, 26, e250-e252.	1.0	4
26	Efficacy and safety of rIX-FP in surgery: An update from a phase 3b extension study. Thrombosis Research, 2020, 193, 139-141.	0.8	3
27	Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa. Expert Opinion on Biological Therapy, 2021, 21, 1165-1171.	1.4	3
28	Acquired Haemophilia A: A 15-Year Single-Centre Experience of Demography, Clinical Features and Outcome. Journal of Clinical Medicine, 2022, 11, 2721.	1.0	3
29	Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain. European Journal of Haematology, 2020, 105, 94-100.	1.1	2
30	Platelet Protein Glycosylation in Immune Thrombocytopenia. Blood, 2018, 132, 2437-2437.	0.6	2
31	Plasmaâ€derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study. Haemophilia, 0, , .	1.0	2
32	Care for children with haemophilia during COVIDâ€19: Data of the PedNet study group. Haemophilia, 2021, 27, e537-e539.	1.0	1
33	Efficacy and safety evaluation of Fanhdi^{Â®}, a plasmaâ€derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study. Haemophilia, 2022, 28, .	1.0	1
34	Glycomic Characterization of Platelets from Patients with Immune Thrombocytopenia. Blood, 2021, 138, 3158-3158.	0.6	1
35	Clinical Efficacy and Safety of FanhdiÂ®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210743.	0.7	1
36	Use of Eltrombopag after Romiplostim in Primary ITP Patients. Blood, 2014, 124, 2790-2790.	0.6	0

#	Article	IF	Citations
37	Successful Discontinuation of Eltrombopag after Complete Remission in Patients with Primary Immune Thrombocytopenia. Blood, 2014, 124, 1465-1465.	0.6	0
38	Usefulness of Eltrombopag in Secondary ITP Patients in Clinical Practice. Blood, 2015, 126, 2263-2263.	0.6	0
39	Efficacy and Safety of Eltrombopag in Persistent and Newly Diagnosed ITP. Blood, 2015, 126, 4657-4657.	0.6	0
40	Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study. Blood, 2016, 128, 3774-3774.	0.6	0
41	99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry. Blood, 2018, 132, 2472-2472.	0.6	0
42	Platelet Dysfunction and Cellular Microparticles May be Involved in the Hipercoagulable State Observed in Obstructive Sleep Apnea Syndrome. Blood, 2018, 132, 5048-5048.	0.6	0
43	Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study. Blood, 2019, 134, 4943-4943.	0.6	0
44	Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A. BMJ Open, 2021, 11, e044997.	0.8	0
45	Evaluation of Platelet Function Defects in Patients with Immune Thrombocytopenia. Blood, 2021, 138, 1021-1021.	0.6	0
46	Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A: Interim Results of a Post-Marketing, Interventional Study. Blood, 2021, 138, 4915-4915.	0.6	0
47	Laboratory Characterization of Unclassified Bleeding Disorders By Non-Conventional Tests. Blood, 2021, 138, 4235-4235.	0.6	0
48	Evaluation of Global Coagulation Tests for Monitoring Bleeding Phenotypes and Response to Treatments in FVII Deficiency. Blood, 2021, 138, 1046-1046.	0.6	0